Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.
Clinical trial NCT01973218 · COMPLETED
Trial details
- NCT number
- NCT01973218
- Sponsor
- Novartis Vaccines
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-11-01
- Primary completion
- 2014-04-01
- Enrollment
- 264
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.